Cardiovascular Drugs and Therapy

, Volume 25, Issue 2, pp 171–182 | Cite as

Role of MicroRNAs in Cardiac Remodeling and Heart Failure



MicroRNAs (miRNAs) are endogenous, short (~22 nucleotide), evolutionarily conserved, non-coding RNAs that regulate gene expression at the post-transcriptional level. Recent evidence suggests that miRNAs are differentially expressed in the failing myocardium and play an important role in progression of heart failure by targeting genes that govern diverse functions in cardiac remodeling process including myocyte hypertrophy, excitation-contraction coupling, increased myocyte loss, and myocardial fibrosis. In addition to their role in adverse cardiac remodeling, miRNAs hold promise as biomarkers of disease progression in heart failure given their presence in circulation and enhanced stability. Further development of miR-based therapeutics may allow for modulation of cardiac and/or systemic levels of specific miRNAs in patients with heart failure . Here, we summarize current knowledge of miRNAs in relation to their role in regulating various aspects of the cardiac remodeling process and discuss their potential use as biomarkers and/or therapeutic targets in heart failure.

Key words

microRNAs Gene silencing Cardiac remodeling Personalized medicine 


Conflict of interest disclosure

This research was supported by research funds from the N.I.H. (RO1 HL58081, HL-73017-0, HL089543-01 and T32HL007081). D.L.M. is a consultant for Miragen (Boulder, Colo.). The authors have no other relevant affiliations or financial involvement in any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.


  1. 1.
    Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007;13:486–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007;129:303–17.PubMedCrossRefGoogle Scholar
  4. 4.
    van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316:575–9.PubMedCrossRefGoogle Scholar
  5. 5.
    van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006;103:18255–60.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436:214–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Xiao J, Luo X, Lin H, et al. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem. 2007;282:12363–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007;100:416–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Cheng YH, Ji RR, Yue JM, et al. MicroRNAs are aberrantly expressed in hypertrophic heart - Do they play a role in cardiac hypertrophy? Am J Pathol. 2007;170:1831–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Tatsuguchi M, Seok HY, Callis TE, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2007;42:1137–41.PubMedCrossRefGoogle Scholar
  11. 11.
    van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 2008;105:13027–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res. 2009;82:21–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13:613–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Matkovich SJ, Van Booven DJ, Youker KA, et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation. 2009;119:1263–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Naga Prasad SV, Duan ZH, Gupta MK, et al. A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem 2009Google Scholar
  16. 16.
    Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol. 2008;45:185–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol Genomics. 2007;31:367–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart - A clue to fetal gene reprogramming in heart failure. Circulation. 2007;116:258–67.PubMedCrossRefGoogle Scholar
  19. 19.
    Morin RD, O’Connor MD, Griffith M, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res. 2008;18:610–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Willenbrock H, Salomon J, Sokilde R, et al. Quantitative miRNA expression analysis: comparing microarrays with next-generation sequencing. RNA. 2009;15:2028–34.PubMedCrossRefGoogle Scholar
  21. 21.
    Dash R, Kadambi V, Schmidt AG, et al. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation. 2001;103:889–96.PubMedGoogle Scholar
  22. 22.
    Urabe Y, Hamada Y, Spinale FG, et al. Cardiocyte contractile performance in experimental biventricular volume-overload hypertrophy. Am J Physiol. 1993;264:H1615–23.PubMedGoogle Scholar
  23. 23.
    Anand IS, Liu D, Chugh SS, et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation. 1997;96:3974–84.PubMedGoogle Scholar
  24. 24.
    Ikeda S, He A, Kong SW, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009;29:2193–204.PubMedCrossRefGoogle Scholar
  25. 25.
    Elia L, Contu R, Quintavalle M, et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation. 2009;120:2377–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008;22:3242–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 2010;106:166–75.PubMedCrossRefGoogle Scholar
  28. 28.
    Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. 2009;13:39–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci USA. 2009;106:12103–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Wang K, Long B, Zhou J, Li PF. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem. 2010;285:11903–12.PubMedCrossRefGoogle Scholar
  32. 32.
    Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest. 1997;100:2362–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Callis TE, Pandya K, Seok HY, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009;119:2772–86.PubMedCrossRefGoogle Scholar
  34. 34.
    Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol. 2009;47:5–14.PubMedCrossRefGoogle Scholar
  35. 35.
    Xu C, Lu Y, Pan Z, et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 2007;120:3045–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Rane S, He M, Sayed D, et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 2009;104:879–86.PubMedCrossRefGoogle Scholar
  37. 37.
    Ren XP, Wu J, Wang X, et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation. 2009;119:2357–66.PubMedCrossRefGoogle Scholar
  38. 38.
    Divakaran V, Adrogue J, Ishiyama M, et al. Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail. 2009;2:633–42.PubMedCrossRefGoogle Scholar
  39. 39.
    Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 2009;104:170–8, p. 6Google Scholar
  40. 40.
    Topkara VK, Mann DL. Clinical applications of miRNAs in cardiac remodeling and heart failure. Personalized Med. 2010;7:531–48.CrossRefGoogle Scholar
  41. 41.
    Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res. 2008;103:1072–83.PubMedCrossRefGoogle Scholar
  42. 42.
    Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3:e3148.PubMedCrossRefGoogle Scholar
  43. 43.
    Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–18.PubMedCrossRefGoogle Scholar
  44. 44.
    Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106:1035–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3:499–506.PubMedCrossRefGoogle Scholar
  46. 46.
    Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3:87–98.PubMedCrossRefGoogle Scholar
  48. 48.
    Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:896–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Suckau L, Fechner H, Chemaly E, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009;119:1241–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Center for Cardiovascular Research, Division of Cardiology, Department of Internal MedicineWashington University School of MedicineSt LouisUSA

Personalised recommendations